Drug Profile
DV 601
Alternative Names: DV-601; HBV therapy - Dynavax; Therapeutic hepatitis B vaccine (DV-601) - Dynavax; Theravax programme - DynavaxLatest Information Update: 16 Oct 2013
Price :
$50
*
At a glance
- Originator Rhein Biotech
- Developer Dynavax Technologies
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 16 Oct 2013 No development reported - Phase-I for Hepatitis B (combination therapy) in Poland (Parenteral)
- 16 Oct 2013 No development reported - Phase-I for Hepatitis B in Germany (Parenteral)
- 29 Dec 2010 DV 601 is still in phase Ib trials for Hepatitis B infection in Poland